A telehealth company partnered with a pharmacy that lacked a required license, raising doubts about the safety and efficacy ...
Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback